Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Precis Engineering + Architecture, an award-winning design firm with locations in Cary, NC, and Ambler, PA, has made a ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

Agenus selected Flex Databases following a rigorous evaluation of various eClinical providers, with Flex’s dedication to innovation, fast deployment, and superior customer service standing out as ...

Leveraging the unique capabilities of Amazon Bedrock in the Sapio lab informatics platform gives customers access to a variety of the latest AI foundational models, including AI21 Labs, Anthropic, and ...

Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer, while Robin Kramer will replace retiring CFO Michael McDonnell.

Novartis follows cross-town rival Roche in partnering with Monte Rosa Therapeutics on so-called molecular glue degraders that ...

The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.

David Epstein has joined Ottimo Pharma, which is developing an antibody drug that board member and longtime Roche dealmaker ...